317 related articles for article (PubMed ID: 35157644)
1. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
[TBL] [Abstract][Full Text] [Related]
2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
3. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
[TBL] [Abstract][Full Text] [Related]
5. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
[TBL] [Abstract][Full Text] [Related]
6. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
[TBL] [Abstract][Full Text] [Related]
9. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
[TBL] [Abstract][Full Text] [Related]
11. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M
Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935
[TBL] [Abstract][Full Text] [Related]
12. A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.
Morehouse ZP; Paulus A; Jasti SA; Bing X
Cureus; 2021 Sep; 13(9):e18153. PubMed ID: 34703690
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
Lewis NM; Self WH; Gaglani M; Ginde AA; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Ghamande SA; McNeal TA; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Busse LW; Lohuis CCT; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Lauring AS; Halasa N; Chappell JD; Grijalva CG; Rice TW; Rhoads JP; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Adams K; Patel MM; Tenforde MW;
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S159-S166. PubMed ID: 35675695
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
[TBL] [Abstract][Full Text] [Related]
16. Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome.
Li HF; Hu SM; Lv M
JAMA; 2022 Jan; 327(4):392-393. PubMed ID: 35076675
[No Abstract] [Full Text] [Related]
17. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
[TBL] [Abstract][Full Text] [Related]
18. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study.
Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M
PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309
[TBL] [Abstract][Full Text] [Related]
20. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
